Company Profiles

driven by the PitchBook Platform

Apellis

Description

Developer of bio-pharmaceutical platform designed to offer novel therapeutic compounds. The company's bio-pharmaceutical platform focuses on the discovery and development of therapeutic compounds that include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration and chronic obstructive pulmonary disease, enabling physicians treat a broad range of autoimmune diseases based upon complement immunotherapy.

2009

Founded

PRIVATE

Status

11-50

Employees

Series E

Latest Deal Type

$60M

Latest Deal Amount

$155M

Total Amount Raised

Description

Developer of bio-pharmaceutical platform designed to offer novel therapeutic compounds. The company's bio-pharmaceutical platform focuses on the discovery and development of therapeutic compounds that include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration and chronic obstructive pulmonary disease, enabling physicians treat a broad range of autoimmune diseases based upon complement immunotherapy.

Website:

www.apellis.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Biotechnology
Drug Delivery

Primary Office

6400 Westwind Way Suite A Crestwood, KY 40014United States +1 (502) 241-4114
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore Apellis's full profile, request a free trial.

Apellis Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

Apellis Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

Apellis Investors (15)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
AJU IB InvestmentVenture CapitalMinority000 0000000 0000
Cormorant Asset ManagementHedge FundMinority000 0000000 0000
Epidarex CapitalVenture CapitalMinority000 0000000 0000
F-Prime Capital PartnersVenture CapitalMinority000 0000000 0000
HealthCare VenturesVenture CapitalMinority000 0000000 0000
AJU IB Investment Venture Capital
Cormorant Asset Management Hedge Fund
Epidarex Capital Venture Capital
F-Prime Capital Partners Venture Capital
HealthCare Ventures Venture Capital

Apellis Executive Team (17)

NameTitleBoard
Seat
Contact
Info
Cedric Francois Ph.DChief Executive Officer, Board Member, President & Co-Founder
Candace DeppProject Manager & Co-Founder
David Watson JDVice President, Corporate Development & General Counsel
Federico Grossi Ph.DVice President, Clinical Development
Nicole PerryVice President, Finance
Cedric Francois Ph.D Chief Executive Officer, Board Member, President & Co-Founder
Candace Depp Project Manager & Co-Founder
David Watson JD Vice President, Corporate Development & General Counsel
Federico Grossi Ph.D Vice President, Clinical Development
Nicole Perry Vice President, Finance

Apellis Board Members (11)

NameRepresentingRoleSinceContact
Info
Alec MachielsSelfCo-Founder & Board Member000 0000
Bihua ChenCormorant Asset ManagementFounder, Chief Executive Officer & Portfolio Manager000 0000
Cedric Francois Ph.DApellisChief Executive Officer, Board Member, President & Co-Founder000 0000
David DarstSelfBoard Member & Co-Founder000 0000
Douglas Onsi JDHealthCare VenturesManaging Director000 0000
Alec Machiels Co-Founder & Board Member Self
Bihua Chen Founder, Chief Executive Officer & Portfolio Manager Cormorant Asset Management
Cedric Francois Ph.D Chief Executive Officer, Board Member, President & Co-Founder Apellis
David Darst Board Member & Co-Founder Self
Douglas Onsi JD Managing Director HealthCare Ventures
Request full access to PitchBook